Technological advances over the past 20 years have created the opportunity to assess, quantify, and routinely monitor research activities without a need to be physically present. Coronavirus has only intensified the discussion about whether to further implement digital technologies and processes into nonclinical studies.
A spirited panel discusses possible approaches, limitations, concerns, and benefits of using remote monitoring for nonclinical research.
Scientific Moderator and Presenters
Kevin McDorman, DVM, DAVCO, PhD
Executive Director, Global Pathology Services
Elizabeth McInnes, BVSc, PhD, FRC Path, MRCVS, FIATP, MBA
Head of Toxicologic Pathology
Armando Irizarry Rovira, DVM, PhD, Diplomate, ACVP
Director of Investigative Toxicology, Nonclinical Study Management, and Pathology
Eli Lilly and Company
View the other webinars in the series:
- IND Perspectives: Approaching Drug Development from Multiple Angles (View On Demand)
- Developing Nonclinical Strategies for Human and Nonhuman Targets (View On Demand)
We are focused on providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.